Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and HypertriglyceridemiaA Randomized, Double-Blind Study

[1] Rosamond W.(2008)Heart disease and stroke statistics: 2008 update A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 e25-146

[2] Flegal K.(2007)Risk of cardiovascular events in patients at optimal values for combined lipid parameters Curr Med Res Opin 23 553-63

[3] Furie K.(1992)Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study Am J Cardiol 70 733-7

[4] Stanek E.J.(1996)Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 213-9

[5] Sarawate C.(2007)Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study Eur J Clin Invest 37 925-32

[6] Willey V.J.(2002)Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 3143-421

[7] Assmann G.(2005)Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267-78

[8] Schulte H.(2004)Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 227-39

[9] Hokanson J.E.(2008)The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 1K-34K

[10] Austin M.A.(2002)Intensive versus moderate lipid lowering with statins after acute coronary syndromes Lancet 360 7-22

[1] Rosamond W.(2008)Heart disease and stroke statistics: 2008 update A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 e25-146

[2] Flegal K.(2007)Risk of cardiovascular events in patients at optimal values for combined lipid parameters Curr Med Res Opin 23 553-63

[3] Furie K.(1992)Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study Am J Cardiol 70 733-7

[4] Stanek E.J.(1996)Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 213-9

[5] Sarawate C.(2007)Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study Eur J Clin Invest 37 925-32

[6] Willey V.J.(2002)Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 3143-421

[7] Assmann G.(2005)Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267-78

[8] Schulte H.(2004)Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 227-39

[9] Hokanson J.E.(2008)The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 1K-34K

[10] Austin M.A.(2002)Intensive versus moderate lipid lowering with statins after acute coronary syndromes Lancet 360 7-22